Hormone therapy and HIV drugs: a delicate balance for transgender women
NCT ID NCT06005610
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how feminizing hormone therapy (estradiol) interacts with HIV medications in transgender women living with HIV. It included 93 participants who were already on HIV treatment and gave them standardized estradiol doses for up to 48 weeks. The goal was to see if hormone therapy affects HIV drug levels and vice versa, to help create better treatment guidelines. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral 17-β estradiol (estrogen hormone therapy)
What this could lead to
If successful, this could help doctors choose HIV medications that work well alongside feminizing hormone therapy, improving health outcomes for transgender women with HIV.
What could go wrong
The study was terminated early, so results are limited. It was also a small, non-randomized trial, meaning findings may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV I INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barranco CRS (11301)
Lima, 4, Peru
-
Case CRS (2501)
Cleveland, Ohio, 44106, United States
-
Chapel Hill CRS (3201)
Chapel Hill, North Carolina, 27599-7215, United States
-
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (31784)
Chiang Mai, 50200, Thailand
-
Greensboro CRS (3203)
Greensboro, North Carolina, 27401, United States
-
Houston AIDS Research Team CRS (31473)
Houston, Texas, 77030, United States
-
Johns Hopkins University CRS (201)
Baltimore, Maryland, 21205, United States
-
New Jersey Medical School Clinical Research Center CRS (31786)
Newark, New Jersey, 07103, United States
-
Nutrición-Mexico CRS (32078)
Mexico City, Tlalpan, 14080, Mexico
-
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (31802)
Bangkok, Patumwan, 10330, Thailand
-
The Ponce de Leon Center CRS (5802)
Atlanta, Georgia, 30308, United States
-
UCSD Antiviral Research Center CRS (701)
San Diego, California, 92103, United States
-
University of California, San Francisco HIV/AIDS CRS (801)
San Francisco, California, 94110, United States
-
University of Colorado Hospital CRS (6101)
Aurora, Colorado, 80045, United States
-
Vanderbilt Therapeutics CRS (3652)
Nashville, Tennessee, 37204, United States
-
Washington University Therapeutics (WT) CRS (2101)
St Louis, Missouri, 63110-1010, United States
-
Weill Cornell Uptown CRS (site 7803)
New York, New York, 10065, United States
-
Whitman-Walker Institute, Inc. CRS (31791)
Washington D.C., District of Columbia, 20005, United States